GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (OTCPK:SHPMF) » Definitions » 14-Day RSI

SHPMF (Shanghai Pharmaceuticals Holding Co) 14-Day RSI : 39.70 (As of Dec. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-13), Shanghai Pharmaceuticals Holding Co's 14-Day RSI is 39.70.

The industry rank for Shanghai Pharmaceuticals Holding Co's 14-Day RSI or its related term are showing as below:

SHPMF's 14-Day RSI is ranked worse than
79.31% of 116 companies
in the Medical Distribution industry
Industry Median: 49.62 vs SHPMF: 39.70

Competitive Comparison of Shanghai Pharmaceuticals Holding Co's 14-Day RSI

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co's 14-Day RSI Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's 14-Day RSI falls into.



Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Shanghai Pharmaceuticals Holding Co 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pharmaceuticals Holding Co Business Description

Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2023, medical distribution is the largest segment, accounting for 89.8% of total revenue. It also has coverage of 31 provinces and cities nationwide.